DAWN vs INCY · rev $131.2M vs P/E 14, rev $5.14B
Day One Biopharmaceuticals Inc (DAWN) versus Incyte Corporation (INCY) — a side-by-side from cached financials, not a winner call.
Day One Biopharmaceuticals Inc (DAWN) is a biotechnology company listed on US.
Incyte Corporation (INCY) is a biotechnology company listed on US.
Latest reported DAWN revenue for 2024-12-31 was $131.2M. Net income was -$95.5M. DAWN currently screens at market cap $656.8M.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
DAWN currently screens at market cap $656.8M. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Not investment advice. Open the DAWN and INCY stock pages for the full models.
Not investment advice.